Form 4: Agenus Inc. Chairman Garo Armen Receives Stock in Lieu of Cash Salary

Garo H. Armen, Chairman and CEO of Agenus Inc., received 4,483 shares of common stock in lieu of cash salary for the pay period ending February 21, 2025.

Summary

• Garo H. Armen, Chairman and CEO of Agenus Inc., received 4,483 shares of Agenus Inc. common stock on February 21, 2025.
• This stock was issued in lieu of his cash salary for the pay period ending on that date, with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• The price of the common stock on February 21, 2025, was $3.32 per share.
• Following the transaction, Armen directly owns 142,051 shares.
• Armen also indirectly owns 31,298 shares through his IRA accounts and 28,950 shares as trustee and investment authority for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The acceptance of stock in lieu of cash could be seen as a positive sign, but it's not definitively bullish.

Positives

• The acceptance of stock in lieu of cash salary by the Chairman and CEO could be interpreted as a sign of confidence in the company's future prospects.
• The shares are fully vested upon issuance, aligning the executive's interests with those of the shareholders.

Industry Context

This type of transaction, where executives receive stock in lieu of cash, is not uncommon in the biotech industry, especially for companies focused on long-term growth. It aligns management's interests with shareholders and conserves cash.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation to attract and retain talent, especially during early stages when cash flow is limited.
• Comparing Agenus's stock compensation practices to those of similar-sized biotech firms (e.g., those with market caps between $500 million and $1 billion) would provide a better benchmark.
• Companies like Iovance Biotherapeutics, Gritstone Bio, and Adaptimmune Therapeutics are potential comparables in terms of market capitalization and focus on immuno-oncology.

Stakeholder Impact

• Shareholders may view the acceptance of stock in lieu of cash salary positively, as it aligns management's interests with theirs.
• Employees may see it as a sign of the company's commitment to conserving cash and investing in future growth.

Key Dates